James C. Hogg

Last updated
James C Hogg 2013 James C Hogg.jpg
James C Hogg 2013

James C. Hogg

OC
Born1935
NationalityCanadian
Known forLung disease research
Children Robert S. Hogg
AwardsOfficer of the Order of Canada, Queen Elizabeth II’s Diamond Jubilee Medal, Canada Gairdner Wightman Award, Royal Society of Canada
Scientific career
FieldsLung disease
InstitutionsCentre for Heart Lung Innovation

James C. Hogg OC (born December 3, 1935) is a Canadian physician and one of Canada's leading pulmonary pathologists. [1] [2] Hogg has been recognized for his research into Chronic Obstructive Pulmonary Disease. [3] [4] [5] [6] He received the Canada Gairdner Wightman Award in 2013. [7] He became an officer of the Order of Canada in 2005 and was named to the Canadian Medical Hall of Fame in 2010. [1] He also received the Queen Elizabeth II’s Diamond Jubilee Medal. [8]

Born in Winnipeg, Manitoba, [1] Hogg studied medicine at the University of Manitoba and McGill University. He completed his residency at the Massachusetts General Hospital and McGill. [9] Hogg became an assistant professor in pathology at McGill in 1971 and moved to the University of British Columbia (UBC) in 1977. [10] He became a fellow of the Royal College of Physicians and Surgeons of Canada in 1974 and of the Royal Society of Canada in 1992. [9] He is the principal investigator at the University of British Columbia Centre for Heart Lung Innovation at St. Paul's Hospital and professor emeritus in the Department of Pathology and Laboratory Medicine at UBC. [7]

Related Research Articles

<span class="mw-page-title-main">Respiratory failure</span> Inadequate gas exchange by the respiratory system

Respiratory failure results from inadequate gas exchange by the respiratory system, meaning that the arterial oxygen, carbon dioxide, or both cannot be kept at normal levels. A drop in the oxygen carried in the blood is known as hypoxemia; a rise in arterial carbon dioxide levels is called hypercapnia. Respiratory failure is classified as either Type 1 or Type 2, based on whether there is a high carbon dioxide level, and can be acute or chronic. In clinical trials, the definition of respiratory failure usually includes increased respiratory rate, abnormal blood gases, and evidence of increased work of breathing. Respiratory failure causes an altered mental status due to ischemia in the brain.

<span class="mw-page-title-main">Pulmonology</span> Study of respiratory diseases

Pulmonology, pneumology or pneumonology is a medical specialty that deals with diseases involving the respiratory tract. It is also known as respirology, respiratory medicine, or chest medicine in some countries and areas.

<span class="mw-page-title-main">Diabetic nephropathy</span> Chronic loss of kidney function

Diabetic nephropathy, also known as diabetic kidney disease, is the chronic loss of kidney function occurring in those with diabetes mellitus. Diabetic nephropathy is the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD) globally. The triad of protein leaking into the urine, rising blood pressure with hypertension and then falling renal function is common to many forms of CKD. Protein loss in the urine due to damage of the glomeruli may become massive, and cause a low serum albumin with resulting generalized body swelling (edema) so called nephrotic syndrome. Likewise, the estimated glomerular filtration rate (eGFR) may progressively fall from a normal of over 90 ml/min/1.73m2 to less than 15, at which point the patient is said to have end-stage renal disease. It usually is slowly progressive over years.

<span class="mw-page-title-main">Respiratory disease</span> Disease of the respiratory system

Respiratory diseases, or lung diseases, are pathological conditions affecting the organs and tissues that make gas exchange difficult in air-breathing animals. They include conditions of the respiratory tract including the trachea, bronchi, bronchioles, alveoli, pleurae, pleural cavity, the nerves and muscles of respiration. Respiratory diseases range from mild and self-limiting, such as the common cold, influenza, and pharyngitis to life-threatening diseases such as bacterial pneumonia, pulmonary embolism, tuberculosis, acute asthma, lung cancer, and severe acute respiratory syndromes, such as COVID-19. Respiratory diseases can be classified in many different ways, including by the organ or tissue involved, by the type and pattern of associated signs and symptoms, or by the cause of the disease.

Airway obstruction is a blockage of respiration in the airway that hinders the free flow of air. It can be broadly classified into being either in the upper airway (UPA) or lower airway (LOA).

Occupational lung diseases are work-related, lung conditions that have been caused or made worse by the materials a person is exposed to within the workplace. It includes a broad group of diseases, including occupational asthma, industrial bronchitis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, inhalation injury, interstitial lung diseases, infections, lung cancer and mesothelioma. These diseases can be caused directly or due to immunological response to an exposure to a variety of dusts, chemicals, proteins or organisms.

<span class="mw-page-title-main">Bronchitis</span> Inflammation of the large airways in the lungs

Bronchitis is inflammation of the bronchi in the lungs that causes coughing. Bronchitis usually begins as an infection in the nose, ears, throat, or sinuses. The infection then makes its way down to the bronchi. Symptoms include coughing up sputum, wheezing, shortness of breath, and chest pain. Bronchitis can be acute or chronic.

<span class="mw-page-title-main">Obstructive lung disease</span> Category of respiratory disease characterized by airway obstruction

Obstructive lung disease is a category of respiratory disease characterized by airway obstruction. Many obstructive diseases of the lung result from narrowing (obstruction) of the smaller bronchi and larger bronchioles, often because of excessive contraction of the smooth muscle itself. It is generally characterized by inflamed and easily collapsible airways, obstruction to airflow, problems exhaling, and frequent medical clinic visits and hospitalizations. Types of obstructive lung disease include; asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD). Although COPD shares similar characteristics with all other obstructive lung diseases, such as the signs of coughing and wheezing, they are distinct conditions in terms of disease onset, frequency of symptoms, and reversibility of airway obstruction. Cystic fibrosis is also sometimes included in obstructive pulmonary disease.

<span class="mw-page-title-main">FEV1/FVC ratio</span> Ratio used in the diagnosis of lung disease

The FEV1/FVC ratio, also called modified Tiffeneau-Pinelli index, is a calculated ratio used in the diagnosis of obstructive and restrictive lung disease. It represents the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC). FEV1/FVC ratio first proposed by E.A. Haensler in 1950. The FEV1/FVC index should not be confused with the FEV1/VC index as they are different, although both are intended for diagnosing airway obstruction. Current recommendations for diagnosing pulmonary function recommend using the modified Tiffeneau-Pinelli index. This index is recommended to be represented as a decimal fraction with two digits after the decimal point.

<span class="mw-page-title-main">Acute exacerbation of chronic obstructive pulmonary disease</span> Medical condition

An acute exacerbation of chronic obstructive pulmonary disease, or acute exacerbations of chronic bronchitis (AECB), is a sudden worsening of chronic obstructive pulmonary disease (COPD) symptoms including shortness of breath, quantity and color of phlegm that typically lasts for several days.

The BODE index, for Body-mass index, airflow Obstruction, Dyspnea, and Exercise, is a multidimensional scoring system and capacity index used to test patients who have been diagnosed with chronic obstructive pulmonary disease (COPD) and to predict long-term outcomes for them. The index uses the four factors to predict risk of death from the disease.

<span class="mw-page-title-main">Tiotropium bromide</span> Long-acting bronchodilator in the maintenance of COPD and asthma

Tiotropium bromide, sold under the brand name Spiriva among others, is a long-acting bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Specifically it is used during periods of breathing difficulty to prevent them from getting worse, rather than to prevent them from happening. It is used by inhalation through the mouth. Onset typically begins within half an hour and lasts for 24 hours.

<span class="mw-page-title-main">Chronic obstructive pulmonary disease</span> Lung disease involving long-term poor airflow

Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms and airflow limitation. The main symptoms of COPD include shortness of breath and a cough, which may or may not produce mucus. COPD progressively worsens, with everyday activities such as walking or dressing becoming difficult. While COPD is incurable, it is preventable and treatable. The two most common types of COPD are emphysema and chronic bronchitis and have been the two classic COPD phenotypes. Emphysema is defined as enlarged airspaces (alveoli) whose walls have broken down resulting in permanent damage to the lung tissue. Chronic bronchitis is defined as a productive cough that is present for at least three months each year for two years. Both of these conditions can exist without airflow limitation when they are not classed as COPD. Emphysema is just one of the structural abnormalities that can limit airflow and can exist without airflow limitation in a significant number of people. Chronic bronchitis does not always result in airflow limitation but in young adults who smoke the risk of developing COPD is high. Many definitions of COPD in the past included emphysema and chronic bronchitis, but these have never been included in GOLD report definitions. Emphysema and chronic bronchitis remain the predominant phenotypes of COPD but there is often overlap between them and a number of other phenotypes have also been described. COPD and asthma may coexist and converge in some individuals. COPD is associated with low-grade systemic inflammation.

Interventional neuroradiology (INR) also known as neurointerventional surgery (NIS), endovascular therapy (EVT), endovascular neurosurgery, and interventional neurology is a medical subspecialty of neurosurgery, neuroradiology, intervention radiology and neurology specializing in minimally invasive image-based technologies and procedures used in diagnosis and treatment of diseases of the head, neck, and spine.

<span class="mw-page-title-main">Jennifer Gardy</span> Canadian biochemist

Jennifer Gardy is a Canadian scientist, educator and broadcaster, with expertise in the fields of molecular biology, biochemistry, and bioinformatics. Since February 2019 she has been the Deputy Director, Surveillance, Data, and Epidemiology on the Global Health: Malaria team at the Bill & Melinda Gates Foundation. She was previously an associate professor at the University of British Columbia's School of Population and Public Health, a Canada Research Chair in Public Health Genomics, and a Senior Scientist at the BC Centre for Disease Control. She is an occasional host of CBC's The Nature of Things, a science communicator, and a children's book author. She was elected to the National Academy of Medicine in 2021 as an International Member.

Richard Margolese, MD, CM FRCS (C), is a Canadian scientist and has been a leader of multiple research studies that have changed the standard treatment for early-stage breast cancer. He is a native of Montreal, Canada.

<span class="mw-page-title-main">Oriol Mitjà</span> Catalan researcher

Oriol Mitjà i Villar is a Catalan-born Spanish researcher and consultant physician in internal medicine and infectious diseases with expertise in poverty-related tropical diseases. He has conducted research at the Lihir Medical Centre in Papua New Guinea since 2010 on new diagnostic and therapeutic tools to eradicate yaws. He was awarded the Princess of Girona Award in the scientific research category. Currently at the Germans Trias i Pujol Research Institute, Mitjà is conducting research on SARS-CoV-2 coronavirus disease (COVID-19) and strategies to control the infection at a community level.

Catharina Boehme is the Assistant Director-General for External Relations and Governance of the World Health Organization. She previously served as WHO Chef de Cabinet, and is known for her work in developing diagnostic tests for diseases such as tuberculosis and for advocating for increased testing for the COVID-19 disease.

David W. Denning is a British retired professor of infectious diseases and global health and medical mycology at the University of Manchester. He was the founding president, executive director and chief executive of Global Action For Fungal Infections (GAFFI) (2013-2023), which focusses on the global impact of fungal disease.

<span class="mw-page-title-main">Asthma trigger</span>

Asthma triggers are factors or stimuli that provoke the exacerbation of asthma symptoms or increase the degree of airflow disruption, which can lead to an asthma attack. An asthma attack is characterized by an obstruction of the airway, hypersecretion of mucus and bronchoconstriction due to the contraction of smooth muscles around the respiratory tract. Its symptoms include a wide range of manifestations such as breathlessness, coughing, a tight chest and wheezing.

References

  1. 1 2 3 "Dr. James C. Hogg". Canadian Medical Hall of Fame. 2010. Archived from the original on July 28, 2014. Retrieved August 14, 2014.
  2. "Dr. James Cameron Hogg".
  3. Agustí, Alvar; Hogg, James C. (September 26, 2019). Drazen, Jeffrey M. (ed.). "Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease". New England Journal of Medicine. 381 (13): 1248–1256. doi:10.1056/NEJMra1900475. ISSN   0028-4793. PMID   31553836. S2CID   203437092.
  4. McDonough, John E.; Yuan, Ren; Suzuki, Masaru; Seyednejad, Nazgol; Elliott, W. Mark; Sanchez, Pablo G.; Wright, Alexander C.; Gefter, Warren B.; Litzky, Leslie; Coxson, Harvey O.; Paré, Peter D.; Sin, Don D.; Pierce, Richard A.; Woods, Jason C.; McWilliams, Annette M. (October 27, 2011). "Small-Airway Obstruction and Emphysema in Chronic Obstructive Pulmonary Disease". New England Journal of Medicine. 365 (17): 1567–1575. doi:10.1056/NEJMoa1106955. ISSN   0028-4793. PMC   3238466 . PMID   22029978.
  5. Hogg, James C.; Chu, Fanny; Utokaparch, Soraya; Woods, Ryan; Elliott, W. Mark; Buzatu, Liliana; Cherniack, Ruben M.; Rogers, Robert M.; Sciurba, Frank C.; Coxson, Harvey O.; Paré, Peter D. (June 24, 2004). "The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease". New England Journal of Medicine. 350 (26): 2645–2653. doi: 10.1056/NEJMoa032158 . ISSN   0028-4793. PMID   15215480.
  6. Hogg, James C.; Macklem, Peter T.; Thurlbeck, W. M. (June 20, 1968). "Site and Nature of Airway Obstruction in Chronic Obstructive Lung Disease". New England Journal of Medicine. 278 (25): 1355–1360. doi:10.1056/NEJM196806202782501. ISSN   0028-4793. PMID   5650164.
  7. 1 2 "Dr. James Hogg given national award for leadership in medicine". University of British Columbia. March 20, 2013.
  8. "James Cameron Hogg".
  9. 1 2 "James C. Hogg MD, PhD". St. Paul's Hospital UBC. Archived from the original on August 19, 2014. Retrieved August 14, 2014.
  10. "James C. Hogg". Canadian Academy of Health Sciences.